Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer research advocacy: past, present, and future.
Perlmutter J, Bell SK, Darien G. Perlmutter J, et al. Cancer Res. 2013 Aug 1;73(15):4611-5. doi: 10.1158/0008-5472.CAN-12-4553-T. Epub 2013 May 29. Cancer Res. 2013. PMID: 23720053 Review.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. DeMichele A, et al. Among authors: perlmutter j. Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24. Clin Cancer Res. 2015. PMID: 25712686 Free PMC article.
Involving Advocates in Cancer Research.
Perlmutter J, Roach N, Smith ML. Perlmutter J, et al. Semin Oncol. 2015 Oct;42(5):681-5. doi: 10.1053/j.seminoncol.2015.07.008. Epub 2015 Jul 9. Semin Oncol. 2015. PMID: 26433549 Review.
Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer.
Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, Mumber M, Perlmutter J, Seely D, Sen A, Zick SM, Tripathy D; Society for Integrative Oncology. Greenlee H, et al. Among authors: perlmutter j. J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58. doi: 10.1093/jncimonographs/lgu041. J Natl Cancer Inst Monogr. 2014. PMID: 25749602 Free PMC article.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Whelan TJ, Wolff AC, Woodgett JR, Kalinsky K, Hayes DF. Dowling RJO, et al. Among authors: perlmutter j. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz049. doi: 10.1093/jncics/pkz049. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337478 Free PMC article.
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Among authors: perlmutter j. Clin Cancer Res. 2024 Jun 3;30(11):2444-2451. doi: 10.1158/1078-0432.CCR-23-2928. Clin Cancer Res. 2024. PMID: 38470545 Free PMC article.
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Rugo HS, et al. Among authors: perlmutter j. Breast Cancer Res Treat. 2025 Feb;209(3):487-492. doi: 10.1007/s10549-024-07555-9. Epub 2024 Dec 3. Breast Cancer Res Treat. 2025. PMID: 39625569 Free PMC article. Clinical Trial.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Thorat MA, Whelan TJ, Wolff AC, Woodgett JR, Sparano JA, Goodwin PJ. Dowling RJO, et al. Among authors: perlmutter j. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz050. doi: 10.1093/jncics/pkz050. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337479 Free PMC article.
Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.
Le-Rademacher J, Mohile S, Unger J, Hudson MF, Foster J, Lichtman S, Perlmutter J, Dotan E, Extermann M, Dodd K, Tew W, Klepin H, Wildes TM, Sedrak MS, Jatoi A, Little RF. Le-Rademacher J, et al. Among authors: perlmutter j. J Natl Cancer Inst Monogr. 2022 Dec 15;2022(60):135-141. doi: 10.1093/jncimonographs/lgac023. J Natl Cancer Inst Monogr. 2022. PMID: 36519818 Free PMC article.
693 results